These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 19841190)

  • 21. Bortezomib in multiple myeloma.
    Mateos MV; San Miguel JF
    Best Pract Res Clin Haematol; 2007 Dec; 20(4):701-15. PubMed ID: 18070714
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Aggravated post-herpetic neuralgia due to bortezomib].
    Kirizume K; Imataki O; Shintani T; Fujihara S; Waki F; Ohue Y; Ohnishi H
    Rinsho Ketsueki; 2008 May; 49(5):331-4. PubMed ID: 18572810
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proteasome inhibition by bortezomib decreases proliferation and increases apoptosis in ovarian granulosa cell tumors.
    Chu S; Alexiadis M; Fuller PJ
    Reprod Sci; 2009 Apr; 16(4):397-407. PubMed ID: 19087975
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells.
    Altun M; Galardy PJ; Shringarpure R; Hideshima T; LeBlanc R; Anderson KC; Ploegh HL; Kessler BM
    Cancer Res; 2005 Sep; 65(17):7896-901. PubMed ID: 16140960
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites.
    Pekol T; Daniels JS; Labutti J; Parsons I; Nix D; Baronas E; Hsieh F; Gan LS; Miwa G
    Drug Metab Dispos; 2005 Jun; 33(6):771-7. PubMed ID: 15764713
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide.
    O'Connor OA; Smith EA; Toner LE; Teruya-Feldstein J; Frankel S; Rolfe M; Wei X; Liu S; Marcucci G; Chan KK; Chanan-Khan A
    Clin Cancer Res; 2006 May; 12(9):2902-11. PubMed ID: 16675587
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of bortezomib in the treatment of lymphoma.
    Barr P; Fisher R; Friedberg J
    Cancer Invest; 2007 Dec; 25(8):766-75. PubMed ID: 18058474
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions.
    Boissy P; Andersen TL; Lund T; Kupisiewicz K; Plesner T; Delaissé JM
    Leuk Res; 2008 Nov; 32(11):1661-8. PubMed ID: 18394701
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis.
    Neubert K; Meister S; Moser K; Weisel F; Maseda D; Amann K; Wiethe C; Winkler TH; Kalden JR; Manz RA; Voll RE
    Nat Med; 2008 Jul; 14(7):748-55. PubMed ID: 18542049
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype.
    Colado E; Alvarez-Fernández S; Maiso P; Martín-Sánchez J; Vidriales MB; Garayoa M; Ocio EM; Montero JC; Pandiella A; San Miguel JF
    Haematologica; 2008 Jan; 93(1):57-66. PubMed ID: 18166786
    [TBL] [Abstract][Full Text] [Related]  

  • 31. G(alpha)12/13 inhibition enhances the anticancer effect of bortezomib through PSMB5 downregulation.
    Yang YM; Lee S; Nam CW; Ha JH; Jayaraman M; Dhanasekaran DN; Lee CH; Kwak MK; Kim SG
    Carcinogenesis; 2010 Jul; 31(7):1230-7. PubMed ID: 20478922
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BCL-2 family regulation by the 20S proteasome inhibitor bortezomib.
    Fennell DA; Chacko A; Mutti L
    Oncogene; 2008 Feb; 27(9):1189-97. PubMed ID: 17828309
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential sensitivity of breast cancer and melanoma cells to proteasome inhibitor Velcade.
    Yerlikaya A; Erin N
    Int J Mol Med; 2008 Dec; 22(6):817-23. PubMed ID: 19020781
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
    Aghajanian C; Blessing JA; Darcy KM; Reid G; DeGeest K; Rubin SC; Mannel RS; Rotmensch J; Schilder RJ; Riordan W;
    Gynecol Oncol; 2009 Nov; 115(2):215-20. PubMed ID: 19712963
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular and functional dissection of the H-2Db-restricted subdominant cytotoxic T-cell response to lymphocytic choriomeningitis virus.
    Hudrisier D; Riond J; Gairin JE
    J Virol; 2001 Mar; 75(5):2468-71. PubMed ID: 11160751
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of proteasome in malignant diseases.
    Moran E; Nencioni A
    J BUON; 2007 Sep; 12 Suppl 1():S95-9. PubMed ID: 17935285
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interleukin-10 plays an early role in generating virus-specific T cell anergy.
    Maris CH; Chappell CP; Jacob J
    BMC Immunol; 2007 Jun; 8():8. PubMed ID: 17570849
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The persisting challenge of selective and specific proteasome inhibition.
    Groll M; Huber R; Moroder L
    J Pept Sci; 2009 Feb; 15(2):58-66. PubMed ID: 19109822
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proteasome inhibition: mechanism of action.
    DeMartino GN
    J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S5-9. PubMed ID: 19791423
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Functional in vivo MHC class II loading by endogenously synthesized glycoprotein during viral infection.
    Oxenius A; Bachmann MF; Mathis D; Benoist C; Zinkernagel RM; Hengartner H
    J Immunol; 1997 Jun; 158(12):5717-26. PubMed ID: 9190921
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.